COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
15 hedge funds and large institutions have $996K invested in COSCIENS Biopharma Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.
68% more capital invested
Capital invested by funds: $591K → $996K (+$405K)
0.01% more ownership
Funds ownership: 0.02% → 0.03% (+0.01%)
6% less funds holding
Funds holding: 16 → 15 (-1)
20% less call options, than puts
Call options by funds: $43K | Put options by funds: $54K
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$200K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$65.3K |
| 3 |
Millennium Management
New York
|
+$19.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.8K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$9.22K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.95K |
| 5 |
Renaissance Technologies
New York
|
-$2.4K |
CSCI Hedge Fund Activity: Q2 2018 in Review
15 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2018, worth a combined $996K — up 68% from $591K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CSCI and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $200K. The largest seller was Susquehanna International Group, cutting an estimated $55.9K.
- 15 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2018, down from 16 in Q1 2018.
- Funds reported $996K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2018, up 68% quarter-over-quarter.
- 3 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2018 and 4 closed out, a net change of -1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2018 was Morgan Stanley, an estimated $200K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2018 was Susquehanna International Group, an estimated $55.9K sold.
Based on aggregated 13F filings for Q2 2018.